FDA Approval of Eversense 365
Received FDA approval for the Eversense 365, the world's first and only 1-year continuous glucose monitor, on September 17.
Strong Early Adoption and Feedback
Early feedback from patients and clinicians on Eversense 365 has been extremely positive, with lead generation exceeding expectations.
Strategic Partnerships and Collaborations
Partnership with Mercy hospital system, which has over 30,000 patients, for system-wide adoption of Eversense 365.
Broad Insurance Coverage
Eversense 365 is covered by nearly all U.S. private insurers and Medicare, totaling over 300 million lives.
Reduced Calibration Requirement
Eversense 365 now requires only once-weekly calibration, making it more competitive in the market.
Positive Financial Outlook for 2025
Expected acceleration in revenue growth for Eversense 365 in 2025 and gross profit margins approaching 30% by year-end 2025.